This study links rare genetic variants to type 2 diabetes risk, emphasizing their role in monogenic diabetes and potential ...

A team led by Mass General Brigham researchers demonstrated that inebilizumab reduced the risk of symptoms by 87% in patients with the rare affliction known as immunoglobulin G4–related disease (IgG4- ...